BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37263806)

  • 21. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
    Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
    Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival.
    Smith JD; Banner NR; Hamour IM; Ozawa M; Goh A; Robinson D; Terasaki PI; Rose ML
    Am J Transplant; 2011 Feb; 11(2):312-9. PubMed ID: 21219570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes.
    Brooks AM; Carter V; Liew A; Marshall H; Aldibbiat A; Sheerin NS; Manas DM; White SA; Shaw JA
    Am J Transplant; 2015 Dec; 15(12):3239-46. PubMed ID: 26227015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human Leukocyte Antigen Compatibility and De Novo Donor-Specific Antibodies in Long-term Renal Transplant Patients With Stable Graft Function.
    Kasimatis E; Fylaktou A; Karampatakis T; Schoina M; Zarras C; Anastasiou A; Papachristou M; Boukla A; Daoudaki M; Fouzas I; Papagianni A
    Transplant Proc; 2019 Mar; 51(2):413-415. PubMed ID: 30879554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of pre-transplant allosensitization on outcomes after lung transplantation.
    Bosanquet JP; Witt CA; Bemiss BC; Byers DE; Yusen RD; Patterson AG; Kreisel D; Mohanakumar T; Trulock EP; Hachem RR
    J Heart Lung Transplant; 2015 Nov; 34(11):1415-22. PubMed ID: 26169666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
    Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
    Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study.
    Hachem RR; Kamoun M; Budev MM; Askar M; Ahya VN; Lee JC; Levine DJ; Pollack MS; Dhillon GS; Weill D; Schechtman KB; Leard LE; Golden JA; Baxter-Lowe L; Mohanakumar T; Tyan DB; Yusen RD
    Am J Transplant; 2018 Sep; 18(9):2285-2294. PubMed ID: 29687961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of human leukocyte antigen antibodies and leukocyte antigen/killer-cell immunoglobulin-like receptor genes in liver transplantation.
    Muro M; Legaz I
    World J Gastroenterol; 2023 Feb; 29(5):766-772. PubMed ID: 36816626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.
    Verleden SE; Vanaudenaerde BM; Emonds MP; Van Raemdonck DE; Neyrinck AP; Verleden GM; Vos R
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29146602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure.
    Mittal S; Page SL; Friend PJ; Sharples EJ; Fuggle SV
    Am J Transplant; 2014 Jul; 14(7):1664-71. PubMed ID: 24866735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of Class I HLA but not preformed low MFI donor specific antibodies correlates with outcomes after first renal transplantation.
    Lobashevsky A; Goggins W; Rosner K; Taber T
    Transpl Immunol; 2017 Aug; 43-44():42-48. PubMed ID: 28629951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study.
    Kovandova B; Slavcev A; Honsova E; Erhartova D; Skibova J; Viklicky O; Trunecka P
    Transpl Int; 2020 Dec; 33(12):1799-1806. PubMed ID: 33020979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome.
    Reinsmoen NL; Mirocha J; Ensor CR; Marrari M; Chaux G; Levine DJ; Zhang X; Zeevi A
    Transplantation; 2017 Jun; 101(6):1215-1221. PubMed ID: 27973391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of two methods to detect donor-specific anti-HLA antibodies after kidney transplant.
    Gil BC; Kulzer ASS; de Moraes P; Toresan R; da Rosa Vicari A; Dos Santos Fagundes I; Merzoni J; Ewald GM; Cardone JM; Silva FG; Manfro RC; Jobim LF
    Transpl Immunol; 2018 Aug; 49():7-11. PubMed ID: 29577967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of C1q-binding donor-specific anti-HLA antibodies on the clinical outcomes of patients after renal transplantation: A systematic review and meta-analysis.
    Kang ZY; Liu C; Liu W; Li DH
    Transpl Immunol; 2022 Jun; 72():101566. PubMed ID: 35257893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
    Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
    J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung intragraft donor-specific antibodies as a risk factor for graft loss.
    Visentin J; Chartier A; Massara L; Linares G; Guidicelli G; Blanchard E; Parrens M; Begueret H; Dromer C; Taupin JL
    J Heart Lung Transplant; 2016 Dec; 35(12):1418-1426. PubMed ID: 27450460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation.
    Jung HY; Kim SH; Seo MY; Cho SY; Yang Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2018 Aug; 33(34):e217. PubMed ID: 30127706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.